1.61

8.05% 0.12

After Hours: 1.61

Actinium Pharmaceuticals Inc (ATNM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Actinium Pharmaceuticals Inc stock is traded at $1.61, with a volume of 413.59K. It is up +8.05% in the last 24 hours and down -1.23% over the past month. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Previous Close:

$1.49

Open:

$1.49

24h Volume:

413.59K

Relative Volume:

2.53

Market Cap:

$50.23M

Revenue:

$81,000

Net Income/Loss:

$-41.04M

P/E Ratio:

-1.2226

EPS:

-1.3169

Net Cash Flow:

$-30.69M

1W Performance:

+3.21%

1M Performance:

-1.23%

6M Performance:

+23.85%

1Y Performance:

-10.56%

1-Day Range:

$1.47

$1.61

1-Week Range:

$1.47

$1.61

52-Week Range:

$1.06

$2.41

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name

Actinium Pharmaceuticals Inc

Sector

Healthcare (1142)

Industry

Biotechnology (639)

Phone

646-767-3870

Address

275 Madison Avenue, 7th Floor, New York, NY

Employee

Twitter

@actiniumpharma

Next Earnings Date

2025-08-08

Latest SEC Filings

ATNM's Discussions on Twitter

Compare ATNM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATNM Actinium Pharmaceuticals Inc	1.61	46.48M	81,000	-41.04M	-30.69M	-1.3169
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
May-14-24	Initiated	Stephens	Overweight
Sep-06-23	Initiated	HSBC Securities	Buy
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight
Aug-25-22	Initiated	B. Riley Securities	Buy
Nov-05-20	Initiated	Alliance Global Partners	Buy
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-14-17	Initiated	Maxim Group	Buy
Aug-25-16	Initiated	ROTH Capital	Buy
Feb-29-16	Initiated	H.C. Wainwright	Buy
Oct-15-15	Initiated	FBR Capital	Outperform
Oct-01-14	Initiated	MLV & Co	Buy
Jul-22-14	Initiated	Canaccord Genuity	Buy

View All

Actinium Pharmaceuticals Inc Stock (ATNM) Latest News

01:14 AM

Actinium Pharmaceuticals (ATNM) Reveals Promising Data for NSCLC Treatment - GuruFocus

01:14 AM

01:04 AM

Actinium Shares Rise After Preclinical Data for ATNM-400 Show Potent Anti-Tumor Activity in Lung Cancer Models - MarketScreener

01:04 AM

12:10 PM

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeut - PR Newswire

12:10 PM

08:30 AM

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PR Newswire

08:30 AM

01:28 AM

What high frequency data says about Actinium Pharmaceuticals Inc.CEO Change & Weekly Momentum Picks - newser.com

01:28 AM

Oct 12, 2025

Is Actinium Pharmaceuticals Inc. (Delaware) stock a contrarian opportunityMarket Risk Report & AI Powered Market Trend Analysis - newser.com

Oct 12, 2025

Oct 10, 2025

Can Actinium Pharmaceuticals Inc. recover in the next quarter2025 Risk Factors & Expert Approved Trade Ideas - newser.com

Oct 10, 2025

Why Actinium Pharmaceuticals Inc. (7AY1) stock remains stableWeekly Trading Summary & Verified Momentum Watchlists - newser.com

Oct 10, 2025

Will Actinium Pharmaceuticals Inc. (Delaware) stock beat international competitionInflation Watch & AI Forecasted Stock Moves - newser.com

Oct 10, 2025

Oct 09, 2025

How geopolitical risks impact Actinium Pharmaceuticals Inc. (7AY1) stockSell Signal & High Return Stock Watch Alerts - newser.com

Oct 09, 2025

Exit strategy if you’re trapped in Actinium Pharmaceuticals Inc.Market Weekly Review & High Conviction Buy Zone Picks - newser.com

Oct 09, 2025

Oct 06, 2025

Will Actinium Pharmaceuticals Inc. stock remain a Wall Street favoritePrice Action & Real-Time Volume Trigger Notifications - newser.com

Oct 06, 2025

Will Actinium Pharmaceuticals Inc. stock recover faster than marketJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com

Oct 06, 2025

Short interest data insights for Actinium Pharmaceuticals Inc.IPO Watch & Risk Managed Investment Signals - newser.com

Oct 06, 2025

Does Actinium Pharmaceuticals Inc. show high probability of rebound2025 Historical Comparison & Risk Managed Trade Strategies - newser.com

Oct 06, 2025

Oct 05, 2025

How big funds are accumulating Actinium Pharmaceuticals Inc. (7AY1) stockQuarterly Growth Report & Safe Investment Capital Preservation Plans - newser.com

Oct 05, 2025

How Actinium Pharmaceuticals Inc. (7AY1) stock performs in volatility spikesRate Cut & Real-Time Volume Analysis - newser.com

Oct 05, 2025

Why Actinium Pharmaceuticals Inc. (Delaware) stock stays undervaluedJuly 2025 Selloffs & Smart Investment Allocation Insights - newser.com

Oct 05, 2025

Oct 03, 2025

Actinium Pharmaceuticals Inc. stock trend forecast2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com

Oct 03, 2025

Oct 02, 2025

How to use Fibonacci retracement on Actinium Pharmaceuticals Inc.2025 Retail Activity & Safe Capital Growth Tips - newser.com

Oct 02, 2025

Oct 01, 2025

Published on: 2025-10-01 07:40:56 - newser.com

Oct 01, 2025

Sep 30, 2025

Is Actinium Pharmaceuticals Inc a good long term investmentTechnical Analysis Insights & Trusted Financial Advisors at No Cost - earlytimes.in

Sep 30, 2025